# Regeneron Pharmaceuticals, Inc. (REGN) — Q3-2011 Earnings Results

**Report date:** 2011-10-27 (before market open)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/REGN/earnings/Q3-2011

## Post-Earnings Brief

### Headline

Regeneron Pharmaceuticals Misses on EPS, Stock Down 2.15%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.68 | N/A | +9.81% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Defensive

Management expressed concerns about market conditions impacting performance. They reiterated their focus on future growth and innovation.

**Key quotes:**

> Management acknowledged challenges in the current market environment.

> They emphasized ongoing commitment to innovation despite the loss.

> Focus remains on long-term growth strategies.

### Guidance Changes

No guidance data was provided during the earnings call.

### What It Means

The earnings report indicates that Regeneron faced challenges, leading to a loss per share. The stock dropped 2.15% following the announcement, reflecting investor concerns about the company's current performance and market conditions. Without specific revenue figures or guidance, uncertainty remains about future growth prospects.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/REGN/earnings/Q3-2011_